This clinical trial is focused on studying the effects of a treatment involving two medications, Follitropin delta and Dydrogesterone, on women who are donating their eggs. The study aims to understand how these medications affect the number of egg cells that can be collected from the donors. Follitropin delta is a type of hormone used to stimulate the ovaries, while Dydrogesterone is a hormone that helps prepare the body for pregnancy. The trial will explore how these medications work together during different phases of the menstrual cycle to enhance egg production.

Participants in the study will receive Follitropin delta as a solution for injection, which is administered under the skin using a pre-filled pen. Dydrogesterone will be taken orally in the form of film-coated tablets. The study will compare the effects of these medications when used during the typical follicular phase, which is the first half of the menstrual cycle, and the luteal phase, which is the second half. The goal is to determine the best approach for maximizing the number of egg cells that can be retrieved from donors.

The trial will last for a specific period, during which participants will follow a treatment plan that includes both medications. The study will monitor various factors, such as the number of egg cells collected, the hormonal changes in the body, and the duration of the treatment. This research is important for improving the process of egg donation and could potentially benefit women who are undergoing fertility treatments in the future.